UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 10-K Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 _____________________ For the fiscal year ended Commission file number December 26, 1998 1-4105 BAUSCH & LOMB INCORPORATED (Exact name of registrant as specified in its charter) NEW YORK 16-0345235 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) ONE BAUSCH & LOMB PLACE, ROCHESTER, NEW YORK 14604-2701 (Address of principal executive offices) (Zip Code) Registrant's telephone no., including area code: (716) 338-6000 SECURITIES REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT: Title of each class Name of each exchange on which registered Common Stock, $0.40 par value New York Stock Exchange $200,000,000 6.75% Notes, Due New York Stock Exchange 2004 Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [ X ] No___ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [ X ] The aggregate market value (based on the consolidated tape closing price on February 23, 1999) of the voting stock held by non-affiliates of the registrant was $3,393,433,140. For the sole purpose of making this calculation, the term "non-affiliate" has been interpreted to exclude directors and officers. Such interpretation is not intended to be, and should not be construed to be, an admission by Bausch & Lomb Incorporated or such directors or officers that such directors and officers are "affiliates" of Bausch & Lomb Incorporated, as that term is defined under the Securities Act of 1933. The number of shares of Voting Stock of the registrant, outstanding as of February 23, 1999, was 56,827,357, consisting of 56,171,809 shares of Common Stock and 655,548 shares of Class B stock, which are identical with respect to dividend and liquidation rights, and vote together as a single class for all purposes. DOCUMENTS INCORPORATED BY REFERENCE Parts I and The Bausch & Lomb 1998 Annual Report to II Shareholders for fiscal year ended December 26, 1998 ("Annual Report"). With the exception of the pages of the Annual Report specifically incorporated by reference herein, the Annual Report is not deemed to be filed as a part of this Report on Form 10-K. Part III Bausch & Lomb Incorporated Proxy Statement, dated March 23, 1999 ("Proxy Statement"). With the exception of the pages of the Proxy Statement specifically incorporated by reference herein, the Proxy Statement is not deemed to be filed as part of this Report on Form 10-K. TABLE OF CONTENTS PART I PAGE Item 1. Business 2 Item 2. Properties 5 Item 3. Legal Proceedings 7 Item 4. Submission of Matters to a Vote of Security 7 Holders PART II Item 5. Market for Bausch & Lomb Incorporated's Common Stock and Related Shareholder Matters 8 Item 6. Selected Financial Data 8 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 8 Item 7A. Quantitative and Qualitative Disclosures About Market Risk 8 Item 8. Financial Statements and Supplementary Data 9 Item 9. Changes In and Disagreements With Accountants on Accounting And Financial Disclosure 9 PART III Item 10. Directors and Executive Officers of Bausch & Lomb Incorporated 10 Item 11. Executive Compensation 11 Item 12. Security Ownership of Certain Beneficial Owners and Management 11 Item 13. Certain Relationships and Related Transactions 11 PART IV Item 14. Exhibits, Financial Statement Schedules, and Reports on Form 8-K 12 Signatures 13 Schedules S-1 Exhibit E-1 Index Exhibits (Attached to this Report on Form 10-K) PART I ITEM 1. BUSINESS (a) GENERAL DEVELOPMENT OF BUSINESS Bausch & Lomb Incorporated is a world leader in the development, manufacture and marketing of healthcare products for the eye. Bausch & Lomb was incorporated in the State of New York in 1908 to carry on a business which was established in 1853. Its principal executive offices are located in Rochester, New York. Unless the context indicates otherwise, the terms "Bausch & Lomb" and "company" as used herein refer to Bausch & Lomb Incorporated and its consolidated subsidiaries. Highlights of the general development of the business of Bausch & Lomb during 1998 are discussed below. During the year ending December 26, 1998, the company successfully integrated the newly acquired surgical businesses into its existing product lines and furthered its transition toward becoming a technology-based healthcare company for the eye. Reported revenues for 1998 were $2,363 million, an increase of $447 million or 23% from 1997. Net earnings for 1998 amounted to $25 million, or $0.45 per diluted share, compared to $49 million, or $0.89 per diluted share, reported in 1997. Significant operational matters affecting 1998 included restructuring charges, disposition of a non-core business, and goodwill impairment and purchased in-process research and development (R&D) charges. As described in the 1997 Annual Report on Form 10-K, the company acquired Chiron Vision Corporation for $298 million and the Storz Instrument Company for $370 million in the first quarter of 1998. The purchase price was allocated to net assets acquired and to purchased in-process research and development. In accordance with applicable accounting rules, purchased in-process R&D is required to be expensed and, accordingly a pre-tax charge of $41 million was recorded in the first quarter of 1998. A pre-tax restructuring charge of $11 million was recorded in 1998 related to the restructuring program begun in 1997. In early 1997, the company's board of directors approved plans to further restructure all business segments as well as certain corporate administrative functions. This restructuring effort is expected to significantly reduce the company's fixed cost structure and realign the organization to meet its strategic objectives. Restructuring charges concluded during the second quarter of 1998. In May 1998, the company sold its skin care business to The Andrew Jergens Company for $135 million in cash plus the assumption of certain liabilities. The company recorded a pre- tax gain of $56 million on the transaction. This business marketed the Curel and Soft Sense brands of skin care products. During the third quarter of 1998, the company sold $300 of putable/callable long-term notes with varying maturities and interest rates, and $200 million of 30-year debentures. The proceeds were used to reduce short-term debt. In November 1998, the company announced that as a result of its strategic planning process, an investment-banking firm had been hired to help assess strategic alternatives for the sunglass business. Alternatives to be considered include joint ventures, sale, spin-off, or other business combinations. The business consists of well-known sunglass brands including Ray-Ban, Killer Loop, Arnette and Revo. In the fourth quarter of 1998, the company recorded an impairment charge of $85 million or $1.51 per diluted share, with no associated tax benefit, related to the goodwill acquired as part of the company's Miracle Ear hearing aid business. During 1998, the company began to reassess the strategic value of the business to its total portfolio. Additionally, during the second half of the year, profitability of the business began to decline. In the fourth quarter, the company's senior management publicly announced that it would be focusing on healthcare products for the eye and no longer had the goal of becoming a diversified healthcare company, leading to the decision to divest the business. The combination of these factors, and their impact on projected future cash flows of the business, led to the conclusion that the goodwill had become impaired. (b) FINANCIAL INFORMATION ABOUT OPERATING SEGMENTS Information concerning sales, operating earnings and assets attributable to each of Bausch & Lomb's operating segments is set forth on pages 26-30 and 48-50 of the Annual Report and is incorporated herein by reference. (c) NARRATIVE DESCRIPTION OF BUSINESS Operating Segments Bausch & Lomb's operations are classified into four segments: vision care, pharmaceuticals/surgical, eyewear and healthcare. Below is a description of each segment and information to the extent that it is material to an understanding of the company's business taken as a whole. Additional information can be found on pages 3 and 7-23 of the Annual Report and is incorporated herein by reference. Vision Care - The vision care segment includes contact lenses and lens care products, with lenses comprising approximately 45% and lens care products representing approximately 55% of segment revenues. Vision care products are marketed to licensed eye care professionals, pharmaceutical retailers and mass merchandisers by the company's own sales force and distributors. Pharmaceuticals/Surgical - The pharmaceuticals/surgical segment manufactures and sells generic and proprietary prescription pharmaceuticals with a strategic emphasis in the ophthalmic field and over-the-counter (OTC) ophthalmic medications, and products and equipment for cataract, refractive, and other ophthalmic surgery. Surgical products accounted for approximately 60% of this segment's revenues in 1998 and were entirely incremental to 1997 results. Pharmaceuticals products accounted for approximately 40% of 1998 segment revenues. These products are marketed by the company's sales force and distributed through wholesalers, independent pharmacies, drug stores, food stores, mass merchandisers and hospitals. Eyewear - The eyewear segment includes premium-priced sunglasses and vision accessories. Eyewear products are distributed worldwide through the company's direct sales force, as well as through distributors, wholesalers and manufacturers' representatives. These products are marketed through optical stores, sunglass specialty stores, department stores, catalog showrooms, mass merchandisers and sporting goods stores. Healthcare - Included in this segment are businesses which provide purpose-bred laboratory animals pathogen-free eggs, biomedical products and services and hearing aids. Biomedical products are sold through the company's own sales force to the scientific research community. Hearing aids are distributed primarily through the Miracle-Ear franchise system and company- owned stores. Suppliers and Customers Materials and components in all four of the company's industry segments are purchased from a wide variety of suppliers and the loss of any one supplier would not adversely affect the company's business to a significant extent. No material part of the company's business taken as a whole is dependent upon a single or a few customers. However, in the eyewear segment approximately 12% of segment sales are attributable to Sunglass Hut International and in the vision care segment approximately 9% of segment sales are attributable to Wal- Mart. Patents, Trademarks and Licenses While in the aggregate the company's patents are of material importance to its businesses taken as a whole, no single patent or patent license or group of patent licenses relating to any particular product or process is material to any industry segment. The company actively pursues technology development and acquisition as a means to enhance its competitive position in its business segments. In the vision care segment, Bausch & Lomb has developed significant consumer and eye care professional recognition of products sold under the Bausch & Lomb, ReNu, ReNu MultiPlus, Sensitive Eyes, SeeQuence, Medalist, Boston, Optima FW and SofLens66 trademarks. Bausch & Lomb , Dr. Mann Pharma, Storz Millennium, Technolas, Hydroview and Vitrasert are trademarks receiving substantial consumer recognition in the pharmaceuticals/surgical segment. Ray-Ban, Revo, Wayfarer, Arnette and Killer Loop are trademarks receiving substantial consumer recognition in the eyewear segment. In the healthcare segment, Miracle-Ear, Mirage and Charles River are trademarks receiving significant consumer and industry professional recognition. Seasonality and Working Capital Some seasonality exists for sunglasses in the eyewear segment. The accumulation of inventories of such products in advance of expected shipments reflects the seasonal nature of the products. In general, the working capital practices followed in each of the company's segments are typical of those businesses. Competition Each industry is highly competitive in both U.S. and non-U.S. markets. In all of its segments, Bausch & Lomb competes on the basis of product performance, quality, technology, price, service, warranty and reliability. In the eyewear segment, the company also competes on the basis of style. Research and Development Research and development constitutes an important part of Bausch & Lomb's activities. In 1998, the company's research and development expenditures totaled $92 million, as compared to $67 million in 1997 and $75 million in 1996. Environment Although Bausch & Lomb is unable to predict what legislation or regulations may be adopted or enacted in the future with respect to environmental protection and waste disposal, existing legislation and regulations have had no material adverse effect on its capital expenditures, earnings or competitive position. Capital expenditures for property, plant and equipment for environmental control facilities were not material during 1998 and are not anticipated to be material for 1999 or 2000. Year 2000 Software Compliance Information regarding the identification and resolution of year 2000 data processing issues is set forth on pages 35-36 of the Annual Report and such information is incorporated herein by reference. Number of Employees Bausch & Lomb employed approximately 15,000 persons as of December 26, 1998. (d) FINANCIAL INFORMATION ABOUT FOREIGN AND DOMESTIC OPERATIONS Information as to sales and long-lived assets attributable to U.S. and non-U.S. geographic regions is set forth on pages 31-32 and page 50 of the Annual Report and is incorporated herein by reference. ITEM 2. PROPERTIES The principal manufacturing, distribution and production facilities and other important physical properties of Bausch & Lomb at March 1, 1999 are listed below and are grouped under the principal operating segment to which they relate. Certain properties relate to more than one segment. Except where otherwise indicated by footnote, all properties shown are held in fee and are not subject to major encumbrances. Eyewear Manufacturing Plants Distribution Centers San Antonio, TX San Clemente, CA (2) Guangzhou, China (2) San Antonio, TX New Territories, Hong Kong (2) North Ryde, Australia (2) Bhiwadi, India Guangzhou, China (2) Waterford, Ireland (2) Mississauga, Ontario Canada (2) Pederobba, Italy New Territories, Hong Kong (2) Nuevo Laredo, Mexico (2) Hoofddorp, Netherlands (2) Healthcare Production Facilities Hollister, CA (2) Maribyrnong, Australia (2) Lebanon, CT Melbourne, Australia (2) Preston, CT Woodend, Australia (2) Storrs, CT Brussels, Belgium Voluntown, CT St. Constant, Canada Summerland Key, FL Prague, Czech Republic (2) Colbert, GA (2) Margate, England Eureka, IL West Sussex, England Roanoke, IL Lyon, France Windham, ME St. Aubin-les-Elbeuf, France Southbridge, MA (2) St. Germain, France West Brookfield, MA (2) Extertal, Germany Wilmington, MA Kisslegg, Germany Portage, MI Sulzfeld, Germany O'Fallon, MO Budapest, Hungary (2) Raleigh, NC Calco, Italy Pittsfield, NH Atsugi, Japan Newfield (Lakeview), NJ Hino, Japan Stone Ridge (Kingston), NY Tskuba, Japan (2) Troy, NY (2) Tuhuacan, Mexico Malvern, PA (2) Someren, Netherlands Charleston, SC (2) Barcelona, Spain (2) Houston, TX Uppsala, Sweden (2) Manufacturing Plants Distribution Centers Golden Valley, MN (1) Preston, CT (2) Kitchener, Ontario, Canada (2) Wilmington, MA (2) Golden Valley, MN (1) Pharmaceuticals/Surgical Manufacturing Plants Distribution Centers Claremont, CA (2) Tampa, FL Irvine, CA (2) Earth City, MO (2) Clearwater, FL Artarmon, Australia (2) Tampa, FL Heidelberg, Germany (2) St. Louis, MO Bracknell, United Kingdom (2) Lyon, France (2) Berlin, Germany Munich, Germany (2) Vision Care Manufacturing Plants Distribution Centers Sarasota, FL (1) Rochester, NY (Optics Center) (1) (2) Wilmington, MA (2) Greenville, SC (20 Rochester, NY Lynchburg, VA (2) (Optics Center) (1) (2) North Ryde, Australia (2) Greenville, SC New Territories, Hong Kong (2) Porto Alegre, Brazil Hoofddrop, Netherlands (2) Beijing, China Mississauga, Ontario Canada (2) Bhiwadi, India Livingston, Scotland (2) Waterford, Ireland (2) Milan, Italy Livingston, Scotland (2) Umsong-Gun (Seoul), South Korea Barcelona, Spain Madrid, Spain Hastings, United Kingdom Corporate Facilities Rochester, NY One Bausch & Lomb Place (1) (2) Optics Center (1) (2) 1295 Scottsville Road (2) (1) This facility is financed under a tax-exempt financing arrangement (2) This facility is leased Bausch & Lomb considers that its facilities are suitable and adequate for the operations involved. All facilities are being productively utilized. ITEM 3. LEGAL PROCEEDINGS 1. The company has stipulated to certification by a New York State Supreme Court of a nationwide class of purchasers of Sensitive Eyes Rewetting Drops, Boston Rewetting Drops, ReNu Rewetting Drops and Bausch & Lomb Eye Wash between May 1, 1989 and June 30, 1995. This action arose out of matters commenced in 1994 and 1995 alleging that the company misled consumers in its marketing and sale of those products. On April 21, 1998, the court dismissed all of the plaintiffs' claims. The plaintiffs have appealed this ruling. 2. In several actions, the company is defending its long- standing policy of selling contact lenses only to licensed professionals against claims that it was adopted in conspiracy with others to eliminate alternate channels of trade from the disposable contact lens market. These matters include (i) a consolidated action in the United States District Court for the Middle District of Florida filed in June 1994 by the Florida Attorney General, and now includes claims by the attorneys general for 21 other states, and (ii) individual actions pending in California and Tennessee state courts. The company defends its policy as a lawfully adopted means of ensuring effective distribution of its products and safeguarding consumers' health. ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SHAREHOLDERS Inapplicable. PART II ITEM 5. MARKET FOR BAUSCH & LOMB INCORPORATED'S COMMON STOCK AND RELATED SHAREHOLDER MATTERS The sections entitled "Dividends" and "Quarterly Stock Prices" and table entitled "Selected Financial Data" on pages 34, 37 and 62, respectively, of the Annual Report and the section entitled "Outstanding Shares" on page 1 of the Proxy Statement are incorporated herein by reference. The company's common stock is traded on the New York Stock Exchange. ITEM 6. SELECTED FINANCIAL DATA The table entitled "Selected Financial Data" on page 62 of the Annual Report is incorporated herein by reference. ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The section entitled "Financial Review" on pages 25-36 of the Annual Report is incorporated herein by reference. ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK The company, as a result of its global operating and financing activities, is exposed to changes in interest rates and foreign currency exchange rates that may adversely affect its results of operations and financial position. In seeking to minimize the risks and/or costs associated with such activities, the company manages exposures to changes in interest rates and foreign currency exchange rates primarily through its use of derivatives. The company does not utilize financial instruments for trading or other speculative purposes, nor does it utilize leveraged financial instruments. The company uses foreign currency forward contracts to hedge foreign currency transactions and equity investments in non-U.S. subsidiaries. Of the outstanding contracts for both 1998 and 1997, the foreign currencies purchased were primarily Irish pounds, Singapore and Hong Kong dollars, and with respect to 1997, Swiss Francs. The foreign currencies sold for the same periods were primarily German marks, Netherlands guilders and Singapore dollars. The magnitude and nature of such hedging activities are explained further in Note 14, "Financial Instruments", on pages 57-58 of the Annual Report. A sensitivity analysis to measure the potential impact that a change in foreign currency exchange rates would have, net of hedging activity, on the company's net income indicates that, based on its year-end positions, if the U.S. dollar weakened against all foreign currencies by 10%, the company would incur an after tax loss of less than $1 million. The company enters into interest rate swap and cap agreements to effectively limit exposure to interest rate movements within the parameters of its interest rate hedging policy. This policy requires that interest rate exposure from floating-rate assets be offset by a substantially similar amount of floating-rate liabilities. Interest rate derivatives are used to readjust this natural hedge position whenever it becomes unbalanced beyond policy limits. For foreign currency denominated borrowing and investing transactions, cross-currency interest rate swap contracts are used, which, in addition to exchanging cash flows derived from rates, exchange currencies at both inception and termination of the contract. A sensitivity analysis to measure the potential impact that a change in interest rates would have, net of hedging activity, on the company's net income indicates that a one percentage point increase in interest rates would increase the company's net interest expense by $1.3 million. Counterparties to the financial instruments discussed above expose the company to credit risks to the extent of non- performance. The credit ratings of the counterparties, which consist of a diversified group of major financial institutions, are regularly monitored and thus credit loss arising from counterparty non-performance is not anticipated. ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA The financial statements, including the notes thereto, together with the sections entitled "Report of Independent Accountants" and "Quarterly Results" on pages 38-60, 61 and 37 of the Annual Report, respectively, are incorporated herein by reference. ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE Inapplicable. PART III ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF BAUSCH & LOMB INCORPORATED Information with respect to directors is included in the Proxy Statement on pages 3-7 and such information is incorporated herein by reference. Set forth below are the names, ages (as of March 1, 1999), positions and offices held by, and a brief account of the business experience during the past five years of, each executive officer. Name and Age Position William M. Chairman and Chief Executive Officer since Carpenter (46) January 1999; Chief Executive Officer (1997- 1998); President and Chief Operating Officer (1995-1996); Executive Vice President, Global Business Manager, Eyewear (1995- 1996); President and Chief Executive Officer, Reckitt & Coleman, Inc. (1994- 1995); President and Chief Operating Officer, Reckitt and Coleman, Inc. (1992- 1994). Carl E. Sassano President and Chief Operating Officer since (49) January 1999; Executive Vice President and President - Vision Care (1997-1998); Senior Vice President and Global Business Manager, Vision Care (1996); Global Business Manager, Contact Lens Products (1994-1996); Senior Vice President and President, Contact Lens Division (1994-1996); Senior Vice President and President, Polymer Technology Corporation, a subsidiary of the company (1992-1994). Dwain L. Hahs (46) Executive Vice President and President - Eyewear since April 1997; Senior Vice President, International Operations (1996- 1997); Vice President and President Europe, Middle East and Africa Division (1994-1996). Daryl M. Dickson Senior Vice President, Human Resources since (47) November 1996; Vice President Human Resources (Foods group), Quaker Oats Company (1993-1996). Hakan S. Edstrom Senior Vice President, (48) Surgical/Pharmaceutical since January 1999; Vice President and President, Bausch & Lomb Surgical (December 1997-December 1998); President Hoefer Pharmacia Biotech, Inc. (1997); Senior Vice President, Corporate Ophthalmic Business Development, Pharmacia & Upjohn, Inc. (1996-1997); President and Chief Executive Officer, Pharmacia Ophthalmics Inc. (1989-1996). James C. Foster Senior Vice President since 1994 and (48) President and Chief Executive Officer of Charles River Laboratories, Inc., a subsidiary of the company, since 1991; Vice President (1991-1994). Stephen C. Senior Vice President and Chief Financial McCluski (46) Officer since 1995; Vice President and Controller (1994); President, Outlook Eyewear Company (1992-1994). Thomas M. Senior Vice President and Chief Technical Riedhammer (50) Officer since January 1999; Senior Vice President and President, Worldwide Pharmaceuticals (1998); Senior Vice President and President, Worldwide Pharmaceutical, Surgical, and Hearing Care Products (1994-1998); Vice President (1993- 1994); President, Worldwide Pharmaceuticals (1994). Robert B. Stiles Senior Vice President and General Counsel (49) since June 1997; Staff Vice President and Assistant General Counsel (1994-1997); Assistant General Counsel (1991-1994). Robert D. Vice President and Chief Information Officer Colangelo (39) since November 1997; Vice President and Controller, Global Vision Care (1996-1997); Vice President and Controller, Contact Lens Division (1995-1996); General Manager, Venezuela and Colombia (1992-1995). Jurij Z. Kushner Vice President, Controller since 1995; Vice (48) President, Operations, Personal Products Division (1994-1995); Vice President and Controller, Personal Products Division (1992- 1994). All officers serve on a year-to-year basis through the day of the annual meeting of shareholders of the company, and there is no arrangement or understanding among any of the officers of the company and any other persons pursuant to which such officer was selected as an officer. ITEM 11. EXECUTIVE COMPENSATION The portions of the "Executive Compensation" section entitled "Report of the Committee on Management", "Compensation Tables" and "Defined Benefit Retirement Plans", the second and third paragraphs of the section entitled "Board of Directors", the graph entitled "Comparison of Five-Year Cumulative Total Shareholder Return" and the second paragraph of the section entitled "Related Transactions, Employment Contracts and Termination of Employment and Change in Control Arrangements" included in the Proxy Statement on pages 10-14, 15-17, 18-20, 2, 18 and 20 respectively, are incorporated herein by reference. ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT The section entitled "Security Ownership of Certain Beneficial Owners and Directors and Executive Officers" in the Proxy Statement on page 8-10 is incorporated herein by reference. ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS The first paragraph of the section entitled "Related Transactions, Employment Contracts and Termination of Employment and Change in Control Arrangements" on page 20 of the Proxy Statement is incorporated herein by reference. PART IV ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K The following documents or the portions thereof indicated are filed as a part of this report. (a) INDEX TO FINANCIAL STATEMENTS AND FINANCIAL STATEMENT SCHEDULES COVERED BY REPORTS OF INDEPENDENT ACCOUNTANTS. 1. Data incorporated by reference in Page in Item 8 from the Annual Report Annual Report Report of Independent Accountants 61 Balance Sheet at December 26, 1998 and 39 December 27, 1997 For the years ended December 26, 1998, December 27, 1997 and December 28, 1996 Statement of Income 38 Statement of Cash Flows 40 Statement of Changes in Shareholder's Equity 41 Notes to Financial Statements 42-60 2. Filed herewith Report of Independent Accountants on Financial Statement Schedules Exhibit 23 For the years ended December 26, 1998, December 27, 1997 and December 28, 1996: SCHEDULE II-Valuation and Qualifying Accounts Page S-1 All other schedules have been omitted because the required information is not present or not present in amounts sufficient to require submission of the schedule, or because the information required is included in the consolidated financial statements or the notes thereto. (b) REPORTS ON FORM 8-K Inapplicable. (c) ITEM 601 EXHIBITS Those exhibits required to be filed by Item 601 of Regulation S-K are listed in the Exhibit Index immediately preceding the exhibits filed herewith and such listing is incorporated herein by reference. Each of Exhibits (10)-a through (10)-v is a management contract or compensatory plan or arrangement required to be filed as an exhibit to this form pursuant to Item 14(c) of this report. SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BAUSCH & LOMB INCORPORATED Date March 24, 1999 By:/s/ William M. Carpenter William M. Carpenter Chairman and Chief Executive Officer Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. Principal Executive Officer Date: March 24, 1999 By:/s/ William M. Carpenter William M. Carpenter Chairman and Chief Executive Officer Principal Financial Officer Date: March 24, 1999 By:/s/ Stephen C. McCluski Stephen C. McCluski Senior Vice President and Chief Financial Officer Controller Date: March 24, 1999 By:/s/ Jurij Z. Kushner Jurij Z. Kushner, Vice President and Controller Directors Franklin E. Agnew William M. Carpenter Domenico De Sole Jonathan S. Linen Ruth R. McMullin John R. Purcell Linda Johnson Rice Alvin W. Trivelpiece William H. Waltrip Kenneth L. Wolfe Date: March 24, 1999 By:/s/ Robert B. Stiles Robert B. Stiles Attorney-in-Fact Bausch & Lomb Incorporated SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS Reserves for Doubtful Accounts December 26, December 27, December 28, 1998 1997 1996 (Dollar amounts in thousands) Balance at beginning of year $ 14,015 $ 13,278 $ 11,232 Activity for the year: Provision charged to income 8,568 4,310 8,556 (Reductions)/additions resulting from (divestiture)/ acquisition activity 9,868 68 (399) Accounts written off (5,787) (5,179) (6,899) Recoveries on accounts previously written off 144 1,538 788 Balance at end of year $ 26,808 $ 14,015 $ 13,278 EXHIBIT INDEX S-K Document Item 601 No (3)-a Certificate of Incorporation of Bausch & Lomb Incorporated (filed as Exhibit (3)-a to the company's Annual Report on Form 10-K for the fiscal year ended December 29, 1985, File No. 1-4105, and incorporated herein by reference). (3)-b Certificate of Amendment of Bausch & Lomb Incorporated (filed as Exhibit (3)-b to the company's Annual Report on Form 10-K for the fiscal year ended December 31, 1988, File No. 1-4105, and incorporated herein by reference). (3)-c Certificate of Amendment of Bausch & Lomb Incorporated (filed as Exhibit (3)-c to the company's Annual Report on Form 10-K for the fiscal year ended December 26, 1992, File No. 1-4105, and incorporated herein by reference). (3)-d By-Laws of Bausch & Lomb Incorporated, as amended, effective October 26, 1998 (filed as Exhibit (3)-a to the company's Form 10-Q for the quarter ended September 26, 1998, File No. 1-4105, and incorporated herein by reference). (4)-a See Exhibit (3)-a. (4)-b See Exhibit (3)-b. (4)-c See Exhibit (3)-c. (4)-d Form of Indenture, dated as of September 1, 1991, between the company and Citibank, N.A., as Trustee, with respect to the company's Medium-Term Notes (filed as Exhibit 4-(a) to the company's Registration Statement on Form S-3, File No. 33-42858, and incorporated herein by reference). (4)-e Supplemental Indenture No. 1, dated May 13, 1998, between the Company and Citibank N.A. (filed as Exhibit 3.1 to the Company's Current Report on Form 8-K, dated July 24, 1998, File No. 1-4105, and incorporated herein by reference). (4)-f Supplemental Indenture No. 2, dated as of July 29, 1998, between the Company and Citibank N.A. (filed as Exhibit 3.2 to the Company's Current Report on Form 8-K, dated July 24, 1998, File No. 1-4105, and incorporated herein by reference). (10)-a Change of Control Employment Agreement with certain executive officers of the company (filed as Exhibit (10)-a to the company's Annual Report on Form 10-K for the fiscal year ended December 29, 1990, File No. 1-4105, and incorporated herein by reference). (10)-b Change of Control Employment Agreement with certain executive officers of the company (filed as Exhibit (10)-b to the company's Annual Report on Form 10-K for the fiscal year ended December 28, 1996, No. 1-4105, and incorporated herein by reference). (10)-c Amended and restated Supplemental Retirement Income Plan II (filed as Exhibit (10)-f to the company's Annual Report on Form 10-K for the fiscal year ended December 29, 1990, File No. 1-4105, and incorporated herein by reference). (10)-d Supplemental Retirement Income Plan III (filed as Exhibit (10)-g to the company's Annual Report on Form 10-K for the fiscal year ended December 26, 1992, File No. 1-4105, and incorporated herein by reference). (10)-e The 1982 Stock Incentive Plan (filed as Exhibit III-F to the company's Annual Report on Form 10-K for the fiscal year ended December 26, 1982, File No. 1-4105, and incorporated herein by reference). (10)-f Amendment to the 1982 Stock Incentive Plan (filed as Exhibit (10)-I to the company's Annual Report on Form 10-K for the fiscal year ended December 31, 1988, File No. 1-4105, and incorporated herein by reference). (10)-g Amendment to the 1982 Stock Incentive Plan (filed as Exhibit (10)-k to the company's Annual Report on Form 10-K for the fiscal year ended December 29, 1990, File No. 1-4105, and incorporated herein by reference). (10)-h The 1987 Stock Incentive Plan (filed as Exhibit I.B to the company's Registration Statement on Form S-8, File No. 33- 15439, and incorporated herein by reference). (10)-i Amendment to the 1987 Stock Incentive Plan (filed as Exhibit (10)-n to the company's Annual Report on Form 10-K for the fiscal year ended December 31, 1988, File No. 1-4105, and incorporated herein by reference). (10)-j Amendment to the 1987 Stock Incentive Plan (filed as Exhibit (10)-n to the company's Annual Report on Form 10-K for the fiscal year ended December 29, 1990, File No. 1-4105, and incorporated herein by reference). (10)-k Amended and restated 1990 Stock Incentive Plan (filed as Exhibit (10)-y to the company's Annual Report on form 10-K for the fiscal year ended December 28, 1996, File No. 1- 4105, and incorporated herein by reference). (10)-l Amended and restated Director Deferred Compensation Plan (filed as Exhibit (10)-bb to the company's Annual Report on Form 10-K for the fiscal year ended December 28, 1996, File No. 1-4105, and incorporated herein by reference). (10)-m Amended and restated Executive Deferred Compensation Plan (filed as Exhibit (10)-cc to the company's Annual Report on Form 10-K for the fiscal year ended December 28, 1996, File No. 1-4105, and incorporated herein by reference). (10)-n Retirement Benefit Restoration Plan (filed as Exhibit (10)-t to the company's Annual Report on Form 10-K for the fiscal year ended December 28, 1991, File No. 1-4105, and incorporated herein by reference). (10)-o Annual Retainer Stock Plan for Non-Employee Directors (filed as Exhibit (10)-dd to the company's Annual Report on Form 10- K for the fiscal year ended December 28, 1996, File No. 1- 4105, and incorporated herein by reference). (10)-p Amended and restated Charles River Laboratories, Inc. Executive Life Insurance / Supplemental Retirement Income Plan (filed as Exhibit (10)-t to the company's Annual Report on Form 10-K for the fiscal year ended December 27, 1997, File No. 1-4105, and incorporated herein by reference). (10)-q Agreement with William H. Waltrip (filed as Exhibit (10)-u to the company's Annual Report on Form 10-K for the fiscal year ended December 27, 1997, File No. 1-4105, and incorporated herein by reference). (10)-r Corporate Officer Separation Plan (filed as Exhibit (10)-v to the company's Annual Report on Form 10-K for the fiscal year ended December 27, 1997, File No. 1-4105, and incorporated herein by reference). (10)-s EVA Management Incentive Compensation Plan (filed as Exhibit (10)-w to the company's Annual Report on Form 10-K for the fiscal year ended December 27, 1997, File No. 1-4105, and incorporated herein by reference). (10)-t 1998 Amendment to the Bausch & Lomb Incorporated 1990 Stock Incentive Plan (filed as Exhibit (10)-a to the company's Form 10-Q for the quarter ended June 27, 1998, File No. 1- 4105, and incorporated herein by reference). (10)-u Management Incentive Compensation Plan (filed as Exhibit (10)-b to the company's Form 10-Q for the quarter ended June 27, 1998, File No. 1-4105, and incorporated herein by reference). (10)-v LTI Deferred Compensation Plan, as amended, effective December 8, 1998 (filed herewith). (11) Statement Regarding Computation of Per Share Earnings (filed herewith). (12) Statement Regarding Computation of Ratio of Earnings to Fixed Charges (filed herewith). (13) The Bausch & Lomb 1998 Annual Report to Shareholders for the fiscal year ended December 26, 1998 (filed herewith). With the exception of the pages of the Annual Report specifically incorporated by reference herein, the Annual Report is not deemed to be filed as a part of this Report on Form 10-K. (21) Subsidiaries (filed herewith). (23) Report of Independent Accountants on Financial Statement Schedules and Consent of Independent Accountants (filed herewith). (24) Power of attorney with respect to the signatures of directors in this Report on Form 10-K (filed herewith). (27) Financial Data Schedule (filed herewith).